Últimas noticias sobre Rivian Automotive (NASDAQ:RIVN) Bolsa

Rivian Automotive

Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues primarily from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.

Nvidia, Meta, Sarepta, D-Wave, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

News

Short Sellers

Markets

LULU

RIVN

TSLA

Explora qué acciones destacaron ayer en Wall Street tras reportes financieros, caídas sorpresivas y nuevos aranceles automotrices.

Lululemon, Applovin, Hertz, Rivian, Tesla: 5 acciones que están en el radar de los inversores

Tesla

Las acciones de Tesla han caído un 19% desde 2022, mientras el mercado sube. ¿Está en riesgo el dominio de Musk?

Apostar contra Tesla (TSLA) desde 2022 fue un éxito: ¿Qué sigue para Elon Musk?

Politics

Tech

XPEV

Startups chinas de vehículos eléctricos suben tras investidura de Trump. Tesla resiste mientras Rivian cae por posibles cambios regulatorios.

Acciones de Nio, Li Auto y Xpeng suben tras anuncios de Trump sobre vehículos eléctricos

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive Inc

Coda Octopus Group Reports $1.4m Engineering Services Order
ORLANDO, FL, April 24, 2025 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. ("CODA" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>), a global market leader in 4D/5D/6D imaging sonar technology and new generation diving technology (DAVD) for real time subsea intelligence, today reported that its UK, Portland based Defense Engineering Services Business, Coda Octopus Martech Limited, recently received an order from one of its established long term customers, a leading and longstanding UK Defense Contractor, for sub-components which will form part of a suite of autonomous mine sweeping systems.

CODA

Coda Octopus Group's Coda Octopus Martech Receives $1.4M Engineering Services Order From UK Defense Contractor

<blockquote>Republic Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBCAA#NASDAQ">RBCAA</a>) reported quarterly earnings of $2.42 per share which beat the analyst consensus estimate of $1.86 by 30.11 percent. This is a 53.16 percent increase over earnings of $1.58 per share from the same period last year.
</blockquote>

Earnings

RBCAA

Republic Bancorp Q1 EPS $2.42 Beats $1.86 Estimate

– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC –
– Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models –
– Demonstrates Internal R&amp;D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease –
– Esperion to Webcast R&amp;D Day Event Today at 9:00 a.m. ET –
Esperion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver disease, today at 9:00 a.m. ET in New York City. A live webcast of the event will also be available. These candidates are novel allosteric inhibitors of ATP citrate lyase (ACLY), a key metabolic enzyme with emerging relevance in hepatic inflammation and fibrosis.
"We are leveraging our deep expertise in ACLY biology to expand our portfolio beyond NEXLETOL&#xAE; (bempedoic acid)/NEXLIZET&#xAE; (bempedoic acid and ezetimibe) and to address the urgent needs of patients living with PSC," said Sheldon Koenig, Chief Executive Officer at Esperion. "Our lead candidates, including ESP-1336, are promising, potential first-in-class allosteric ACLY inhibitors, well-characterized with significant preclinical data, and represent a natural extension of our metabolic franchise. PSC is a rare and progressive liver disease with no approved therapies proven to slow or halt its progression. Our next-generation ACLY inhibitor discovery program was purpose-built to improve potency, selectivity, and guide indication and patient population selection through data-driven innovation."
"ACLY is a promising target in hepatic disease, given its central role in metabolic regulation," said David E. Cohen MD, PhD, Chief, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital. "By modulating acetyl-coenzyme A (acetyl-CoA) levels in multiple hepatobiliary cell types, these inhibitors may disrupt key disease-driving pathways in PSC, offering a potentially transformative approach to treatment."

Biotech

General

ESPR

Esperion Announces The Company Plans To Highlight New Research Supporting Its Lead Development Candidates For The Treatment Of Primary Sclerosing Cholangitis April 24, 2025 Today At 9:00 AM ET In New York City. Also Expands Portfolio With Introduction Of A Novel Program Targeting PSC

COTY

Coty Commences Next Phase Of "All-in to Win" Program

<h3>Gainers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares moved upwards by 51.0% to $0.17 during Thursday's pre-market session. The market value of their outstanding shares is at $8.4 million. </li>
<li>Linkage Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) shares moved upwards by 21.8% to $2.29. The market value of their outstanding shares is at $7.0 million. </li>
<li>Foresight Autonomous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSX#NASDAQ">FRSX</a>) stock rose 12.1% to $0.75. The company's market cap stands at $14.2 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares increased by 8.24% to $1.05. The market value of their outstanding shares is at $20.1 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares moved upwards by 7.95% to $0.24. The market value of their outstanding shares is at $1.6 million. </li>
<li>Hasbro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) shares increased by 7.8% to $56.8. The market value of their outstanding shares is at $7.9 billion. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) stock declined by 91.8% to $0.02 during Thursday's pre-market session. </li>
<li>Autozi Internet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) stock declined by 25.1% to $0.76. The market value of their outstanding shares is at $80.5 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock declined by 12.2% to $0.0. The market value of their outstanding shares is at $2.8 million. </li>
<li>TAL Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) shares decreased by 10.57% to $9.82. The market value of their outstanding shares is at $5.9 billion. The company's, Q4 earnings came out today. </li>
<li>Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) stock fell 9.87% to $5.21. The market value of their outstanding shares is at $545.7 million. </li>
<li>Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) stock fell 9.82% to $0.72. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CURV

FRSX

GNLN

HOFV

LGCB

SBET

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 13.7% to $0.99 during Thursday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares increased by 13.32% to $0.27. The company's market cap stands at $17.4 million. </li>
<li>Avanos Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNS#NYSE">AVNS</a>) stock rose 12.55% to $13.99. The market value of their outstanding shares is at $643.5 million. </li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $375.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) shares rose 8.49% to $19.28. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares rose 8.2% to $0.86. The company's market cap stands at $4.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares decreased by 32.6% to $1.26 during Thursday's pre-market session. The company's market cap stands at $39.3 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) stock decreased by 23.45% to $0.15. The company's market cap stands at $26.7 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 22.44% to $0.54. The company's market cap stands at $17.7 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 15.26% to $3.11. The market value of their outstanding shares is at $5.1 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) shares decreased by 13.05% to $6.0. The market value of their outstanding shares is at $35.1 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock decreased by 12.68% to $1.24. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATRA

AVNS

CERO

ENSC

FORA

GLYC

NUWE

NVCR

RLMD

SONN

XFOR

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock rose 16.3% to $2.35 during Thursday's pre-market session. The company's market cap stands at $3.5 million. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares moved upwards by 13.68% to $3.49. The company's market cap stands at $8.2 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares rose 11.9% to $0.19. The company's market cap stands at $37.5 million. </li>
<li>WF International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WXM#NASDAQ">WXM</a>) stock rose 9.49% to $2.19. The company's market cap stands at $15.1 million. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) shares increased by 7.43% to $0.26. The market value of their outstanding shares is at $6.6 million. </li>
<li>TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) shares increased by 6.8% to $82.52. The market value of their outstanding shares is at $16.1 billion. As per the press release, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) shares fell 15.8% to $1.07 during Thursday's pre-market session. The company's market cap stands at $8.5 million. </li>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) stock declined by 15.68% to $0.22. The company's market cap stands at $21.3 million. </li>
<li>Robert Half (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) stock fell 13.91% to $39.99. The company's market cap stands at $4.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock fell 10.44% to $0.09. The market value of their outstanding shares is at $12.4 million. </li>
<li>Allegion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>) shares decreased by 8.82% to $115.31. The market value of their outstanding shares is at $9.9 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Primech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) stock decreased by 8.53% to $0.75. The market value of their outstanding shares is at $28.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLE

AREB

GPUS

HTOO

LNZA

PMEC

ZONE

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) shares rose 17.5% to $90.55 during Thursday's pre-market session. The company's market cap stands at $2.5 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) stock increased by 15.98% to $2.54. The company's market cap stands at $44.8 million. </li>
<li>Wetouch Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) stock moved upwards by 12.26% to $1.19. The company's market cap stands at $14.1 million. </li>
<li>Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) stock increased by 11.74% to $29.5. The company's market cap stands at $559.9 million. The company's, Q1 earnings came out today. </li>
<li>Materialise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) shares increased by 9.93% to $5.09. The market value of their outstanding shares is at $300.6 million. As per the press release, Q1 earnings came out today. </li>
<li>Pony AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) shares moved upwards by 9.76% to $5.96. The company's market cap stands at $2.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) stock fell 14.3% to $0.15 during Thursday's pre-market session. The market value of their outstanding shares is at $1.2 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares decreased by 10.05% to $1.88. The company's market cap stands at $68.6 million. </li>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) shares declined by 9.4% to $6.01. The market value of their outstanding shares is at $382.4 million. </li>
<li>Nokia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) stock declined by 8.1% to $4.88. The company's market cap stands at $26.3 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) stock declined by 8.02% to $2.87. The market value of their outstanding shares is at $3.3 million. </li>
<li>XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) shares decreased by 7.95% to $3.13. The company's market cap stands at $33.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIXI

BTOG

FARO

MTLS

OBLG

PONY

WETH

ZENA

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

UBER

Uber And Volkswagen To Deploy All-Electric, Fully Autonomous ID Buzz Vehicles

Guidance

ITGR

Integer Holdings Raises FY2025 Adj EPS Guidance from $5.84-$6.20 to $6.15-$6.51 vs $6.06 Est

Stock Split

X4 Pharmaceuticals shares are trading lower after the company announced a 1-for-30 reverse stock split.

Events

RVPH

Reviva To Present Poster On RECOVER Long-Yerm Open Label Extension Trial For Brilaroxazine In Schizophrenia At 2025 ASCP Annual Meeting

X4 Pharmaceuticals Announces 1-for-30 Reverse Stock Split, Which Will Take Effect Apr. 28

<ul>
<li>Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive's nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists.</li>
<li>Northstrive believes the FDA responses encourage a path forward for filing an IND application to conduct a Phase 2 clinical trial in overweight or obese patients.</li>
<li>EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. &nbsp;</li>
</ul>
NEWPORT BEACH, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) (the "Company," "PMGC," "we," or "our"), announced that it has received preliminary responses and commentary from the U.S. Food and Drug Administration ("FDA") regarding its scheduled Type B pre-Investigational New Drug ("pre-IND") meeting. Northstrive initially requested this meeting with the FDA to discuss nonclinical studies and Northstrive Biosciences' clinical development plans for EL-22 administered in combination with GLP-1 receptor agonists. Northstrive believes the FDA's responses support an IND submission for the initiation of a proposed Phase 2 clinical study.

ELAB

Northstrive Biosciences Receives Preliminary Responses And Commentary From FDA Regarding Scheduled Type B Pre-IND Meeting

Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.:
To our valued stockholders,
As we reflect on the Company's progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future holds.
We currently have two ongoing clinical trials for our lead drug, ENV105, which is being tested in patients with prostate cancer in a Phase 2 trial and is being tested in a Phase 1 trial for patients with a type of lung cancer (called EGFR-dependent non-small cell lung cancer). As part of these trials, we are also identifying and confirming biomarkers to identify patients for whom this combined therapy may prove most effective. Our CSO Dr. Neil Bhowmick's lab received $876,000 from the Department of Defense to support a biomarker study for lung cancer patients responsive to ENV105. In addition to our long-standing, close relationship with Cedars Sinai Hospital in Los Angeles, where we are conducting both trials, we have also expanded the prostate trial sites to the University of Utah and City of Hope. We are aiming to be able to discuss safety and interim efficacy results toward the end of the second quarter 2025.
We are also continuing our development work for our proprietary immune response compounds, including KROS101, designed to treat cancers by increasing the killer T cell population while decreasing the suppressor Treg population. We have reported some exciting data on this GITR ligand small molecule agonist at American Association for Cancer Research meetings, the Society for Immunotherapy of Cancer meeting, and at the upcoming American Society of Clinical Oncology meeting.
There remains significant unmet medical needs in both cancer and inflammation. We believe our research will open new paths to help address these serious conditions. Each of the indications we seek to address represent multi-billion-dollar markets. Further, we continue to receive non-dilutive government grants to support research in several of our programs, even in an environment where these types of grants are in jeopardy of drying up due to the macro political environment. Finally, we have a robust intellectual property portfolio that we believe will provide significant protection into the 2030s.
We now have significant research analyst coverage through several investment banks, including EF Hutton, D. Boral, Rodman and Renshaw, Maxim, and HC Wainwright. Further, we will be participating in the D. Boral Healthcare Conference in May and the HC Wainwright Healthcare Conference in September.
Despite recent economic headwinds, we remain financially strong due to our recent private placement and judicious use of funds with non-dilutive funding. Thank you for your continued support and confidence in our mission. We look forward to providing you with regular updates on our progress as we move forward.
Sincerely,
John Yu, M.D. CEO, Kairos Pharma

KAPA

Kairos Pharma Issues Letter To Stockholders; Updates Two Ongoing Clinical Trials For ENV105 For Patients With Prostate Cancer And KROS101 For Cancer Treatment

First Merchants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRME#NASDAQ">FRME</a>) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.91 by 3.3 percent. This is a 10.59 percent increase over earnings of $0.85 per share from the same period last year. The company reported quarterly sales of $160.32 million which missed the analyst consensus estimate of $170.88 million by 6.18 percent. This is a 4.31 percent increase over sales of $153.70 million the same period last year.

Earnings Beats

Earnings Misses

FRME

First Merchants Q1 Adj. EPS $0.94 Beats $0.91 Estimate, Sales $160.32M Miss $170.88M Estimate

Carpenter Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) reported quarterly earnings of $1.88 per share which beat the analyst consensus estimate of $1.74 by 8.05 percent. This is a 57.98 percent increase over earnings of $1.19 per share from the same period last year. The company reported quarterly sales of $727.00 million which missed the analyst consensus estimate of $729.87 million by 0.39 percent. This is a 6.15 percent increase over sales of $684.90 million the same period last year.

Carpenter Tech Q3 Adj. EPS $1.88 Beats $1.74 Estimate, Sales $727.00M Miss $729.87M Estimate

Teck Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.25 by 68 percent. This is a 25 percent decrease over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $1.59 billion which missed the analyst consensus estimate of $1.60 billion by 0.31 percent. This is a 46.10 percent decrease over sales of $2.96 billion the same period last year.

TECK

Teck Resources Q1 Adj. EPS $0.42 Beats $0.25 Estimate, Sales $1.59B Miss $1.60B Estimate

Integer Holdings Q1 Adj. EPS $1.31 Beats $1.24 Estimate, Sales $437.00M Beat $428.70M Estimate

WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a Shareholder Letter addressing R&amp;D trends for inflammasome inhibitors in development, and provides an update on the development status of Inflammasome ASC Inhibitor IC 100. The full text of the letter follows.
ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases, with initial focus on Obesity-associated cardiometabolic conditions as the lead. Plans for indication expansion include treatments for Parkinson's and Alzheimer's diseases, and Multiple Sclerosis. The global drug market for anti-inflammatory biologics was valued at $105 billion in 2024, and it's projected to reach $186 billion by 2034 (Precedence Research). This growth is driven by the rising incidence of chronic inflammatory diseases associated with population aging, lifestyle changes, and environmental factors.

ZVSA

ZyVersa Advances IC 100 Inflammasome Inhibitor for Chronic Inflammatory Diseases

Press Releases

Rivian Certified Collision Network Grants Approval for the Autel IA900 ADAS Calibration System

Rivian Releases Fourth Quarter and Full Year 2024 Financial Results

Rivian Makes Ben & Jerry's Ice Cream Dreams Come True

Sreela Venkataratnam Joins Rivian as Chief Accounting Officer

Rivian Founder and CEO RJ Scaringe to Participate in Wolfe Research Virtual Autos Summit

Rivian Spins out Micromobility Business into New Startup—Also, Inc.

Rivian Releases Q1 2025 Production and Delivery Figures and Sets Date for First Quarter 2025 Financial Results

Rivian CFO to Participate in Bank of America Securities 2025 Automotive Summit

Aidan Gomez Joins Rivian's Board of Directors

GraniteShares 2x Long LCID Daily ETF (LCDL) and GraniteShares 2x Long RIVN Daily ETF (RVNL) Launch Today.

LCDL

LCID

RVNL

AYRO

Cenntro

Chijet Motor Company, Inc. - Ordinary Shares

Chijet Motor Co

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Envirotech Vehicles

Ford Motor

Faraday Future Intelligent Electric Inc. - Class A Common Stock

Faraday Future

Fly-E Group

General Motors

Honda Motor Co

Lucid Group

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

Thor Industries

Toyota Motor

VinFast Auto

Winnebago Industries

Workhorse Gr

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

XPeng

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Rivian Automotive

Noticias

Últimas noticias sobre Rivian Automotive (NASDAQ:RIVN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL